Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$40.29 USD
+0.65 (1.64%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $40.39 +0.10 (0.25%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Income Statements
Fiscal Year end for Structure Therapeutics Inc Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 0 | 0 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 103 | 53 | 38 | 0 | 0 |
Income After Depreciation & Amortization | -103 | -53 | -38 | 0 | 0 |
Non-Operating Income | 13 | 1 | 0 | NA | NA |
Interest Expense | 0 | 0 | 0 | NA | NA |
Pretax Income | -89 | -51 | -38 | NA | NA |
Income Taxes | 0 | 0 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -90 | -51 | -38 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -90 | -51 | -38 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -108 | -53 | -38 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | -6 | -1 | 0 | NA | NA |
Income After Depreciation & Amortization | -103 | -53 | -38 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 110.20 | 9.58 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.81 | -5.51 | NA | NA | NA |
Diluted Net EPS (GAAP) | -2.44 | -16.54 | NA | NA | NA |
Fiscal Year end for Structure Therapeutics Inc Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 33.32 | 32.02 | 30.99 | 26.15 | 25.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | -33.32 | -32.02 | -30.99 | -26.15 | -25.99 |
Non-Operating Income | 7.34 | 6.01 | 6.18 | 2.69 | 2.83 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -25.98 | -26.01 | -24.82 | -23.46 | -23.16 |
Income Taxes | 0.05 | 0.03 | -0.31 | 0.41 | 0.12 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -26.03 | -26.04 | -24.50 | -23.86 | -23.28 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -26.03 | -26.04 | -24.50 | -23.86 | -23.28 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 148.24 | 139.71 | 147.55 | 114.95 | 114.76 |
Diluted EPS Before Non-Recurring Items | -0.18 | -0.19 | -0.17 | -0.21 | -0.20 |
Diluted Net EPS (GAAP) | -0.53 | -0.56 | -0.46 | -0.62 | -0.61 |